LPV/r + TDF/FTC or TDF/3TC — Competitive Intelligence Brief

LPV/r + TDF/FTC or TDF/3TC (LPV/r + TDF/FTC or TDF/3TC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) HIV protease; HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

LPV/r + TDF/FTC or TDF/3TC (LPV/r + TDF/FTC or TDF/3TC) — The HIV Netherlands Australia Thailand Research Collaboration. This combination antiretroviral regimen suppresses HIV replication by inhibiting viral protease and reverse transcriptase enzymes simultaneously.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LPV/r + TDF/FTC or TDF/3TC TARGET	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Lopinavir/ritonavir + nevirapine	Lopinavir/ritonavir + nevirapine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
Atazanavir + 2 NRTIs	Atazanavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs)	HIV protease; HIV reverse transcriptase
Ritonavir boosted Atazanavir + Lamivudine	Ritonavir boosted Atazanavir + Lamivudine	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
ATV/r + TDF/FTC or DRV/r + TDF/FTC	ATV/r + TDF/FTC or DRV/r + TDF/FTC	Juan A. Arnaiz	phase 3	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Atazanavir-Ritonavir/ Stavidine / Lamivudine	Atazanavir-Ritonavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Bristol-Myers Squibb · 3 drugs in this class
2. Juan A. Arnaiz · 2 drugs in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class
5. University of Cologne · 1 drug in this class
6. Amsterdam UMC, location VUmc · 1 drug in this class
7. ViiV Healthcare · 1 drug in this class
8. Drugs for Neglected Diseases · 1 drug in this class